Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2020

May 2020 | 104 pages | ID: S1728E0A3F4EN
Global Markets Direct

Abstracts

Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia – Pipeline Review, H1 2020, provides an overview of the Spinocerebellar Ataxia (Genetic Disorders) pipeline landscape.

Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech and difficulty swallowing.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinocerebellar Ataxia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinocerebellar Ataxia (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 1, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Spinocerebellar Ataxia (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Spinocerebellar Ataxia (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Spinocerebellar Ataxia (SCA) - Overview
Spinocerebellar Ataxia (SCA) - Therapeutics Development
Spinocerebellar Ataxia (SCA) - Therapeutics Assessment
Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development
Spinocerebellar Ataxia (SCA) - Drug Profiles
Spinocerebellar Ataxia (SCA) - Dormant Projects
Spinocerebellar Ataxia (SCA) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Spinocerebellar Ataxia (SCA), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Spinocerebellar Ataxia (SCA) - Pipeline by Allianz Pharmascience Ltd, H1 2020
Spinocerebellar Ataxia (SCA) - Pipeline by Anima Biotech Inc, H1 2020
Spinocerebellar Ataxia (SCA) - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Spinocerebellar Ataxia (SCA), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Allianz Pharmascience Ltd
Anima Biotech Inc
Biohaven Pharmaceutical Holding Company Ltd
BioXcel Corp
Celavie Biosciences LLC
Dystrogen Therapeutics SA
Enzerna Biosciences LLC
Everfront Biotech Inc
Exicure Inc
IntraBio Ltd
Ionis Pharmaceuticals Inc
Lacerta Therapeutics Inc
Sclnow Biotechnology Co Ltd
Seelos Therapeutics, Inc.
Shionogi & Co Ltd
Spark Therapeutics Inc
Steminent Biotherapeutics Inc
UniQure NV
Vybion Inc
Wave Life Sciences Ltd